2026年6月最新影响因子数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
| 热门AI工具： |
论文引言生成
New
AI 写作痕迹检测
Hot
学术改写降重
论文摘要生成
参考文献挖掘工具
审稿意见辅助撰写
|
查看更多AI工具 >> |
| 近期推荐： | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 热 Springer Nature特刊征稿 |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Journal for ImmunoTherapy of Cancer J IMMUNOTHER CANCER （此期刊被最新的JCR期刊SCIE收录） LetPub评分 8.5
68人评分
我要评分
声誉 9.2 影响力 8.1 速度 7.0 | |||||||||||||||||||||||||||||||||||||
| 期刊ISSN | 2051-1426 | 安装APP，查看期刊最新消息
| ||||||||||||||||||||||||||||||||||||
| 2025-2026最新IF （数据来源于网友提供） | 注册或登录后，查看IF | |||||||||||||||||||||||||||||||||||||
| 实时影响因子 | 截止2026年5月06日：10.95 | |||||||||||||||||||||||||||||||||||||
| 2025-2026自引率 | 3.4%点击查看自引率趋势图 | |||||||||||||||||||||||||||||||||||||
| 五年IF （数据来源于网友提供） | 12.297数据由网友[憧憬奶茶]收集提供 | |||||||||||||||||||||||||||||||||||||
| h-index | 36 | |||||||||||||||||||||||||||||||||||||
| CiteScore （ 2026年6月最新版） |
| |||||||||||||||||||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||||||||||||||||||
| 期刊官方网站 | https://jitc.bmj.com/ | |||||||||||||||||||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||||||||||||||||||
| 期刊投稿网址 | https://mc.manuscriptcentral.com/jitc | |||||||||||||||||||||||||||||||||||||
| 作者指南网址 | https://jitc.bmj.com/pages/authors | |||||||||||||||||||||||||||||||||||||
| 该期刊中国学者近期发文 - New | LARS2 reprograms mitochondrial metabolism and epigenetically upregulates MHC-I to boost antitumor immunity in nasopharyngeal carcinoma Author: Yang, Mei; Mo, Yongzhen; Ren, Daixi; Liu, Shun; Yan, Qijia; Shi, Lei; Chen, Pan; Xiang, Bo; He, Rongfang; Fan, Songqing; Zhou, Ming; Tan, Ming; Li, Guiyuan; Zu, Xuyu; Zeng, Zhaoyang; Xiong, Wei Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 8, pp. -. DOI: 10.1136/jitc-2026-015098 DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy Author: Zhao, Yuanyuan; Wang, Qiming; Xiao, Bijing; Jia, Jun; Liu, Xianling; Ma, Shuxiang; Liu, Hong; Zhou, Ting; Yang, Yunpeng; Fang, Wenfeng; Zhang, Li; Huang, Yan Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 8, pp. -. DOI: 10.1136/jitc-2026-015066 AARS1-mediated lactylation reprograms macrophage lipid metabolism to restrict antitumor immunity Author: Xiao, Zhaofeng; Meng, Lijun; Xu, Shengjun; Xu, Nan; Li, Ye; Wang, Jianguo; Tong, Jinyi; Ding, Hongda; Tan, Xiaodong Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 8, pp. -. DOI: 10.1136/jitc-2026-015773 PGE2-mediated NK cell reprogramming drives acquired immunotherapy resistance in lung adenocarcinoma Author: Wang, Yajing; Peng, Chen; Feng, Sitong; Wen, Shaodi; Xu, Cong; Du, Xiaoyue; Jiang, Weiwei; Zou, Renrui; Shi, Yue; Ma, Yuejuan; Xu, Zihan; Jiang, Muxi; Shen, Bo Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 8, pp. -. DOI: 10.1136/jitc-2025-014673 | |||||||||||||||||||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Journal for ImmunoTherapy of Cancer的语言要求，还能让Journal for ImmunoTherapy of Cancer编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Journal for ImmunoTherapy of Cancer编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢（2篇） 。
提交文稿 | |||||||||||||||||||||||||||||||||||||
| 是否OA开放访问 | Yes | |||||||||||||||||||||||||||||||||||||
OA期刊相关信息 | 文章处理费：需要（ USD3180; ） 文章处理费豁免：查看说明 其他费用：没有 期刊主题关键词：tumour immunology、cancer immunotherapy、immunotherapy biomarkers 相关链接：Aims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | |||||||||||||||||||||||||||||||||||||
| 通讯方式 | BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND, WC1H 9JR | |||||||||||||||||||||||||||||||||||||
| 出版商 | BMJ PUBLISHING GROUP | |||||||||||||||||||||||||||||||||||||
| 涉及的研究方向 | Biochemistry, Genetics and Molecular Biology-Molecular Medicine | |||||||||||||||||||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||||||||||||||||||
| 出版周期 | ||||||||||||||||||||||||||||||||||||||
| 出版年份 | 2013 | |||||||||||||||||||||||||||||||||||||
| 年文章数 | 587点击查看年文章数趋势图 | |||||||||||||||||||||||||||||||||||||
| Gold OA文章占比 | 100.00% | |||||||||||||||||||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 95.06% | |||||||||||||||||||||||||||||||||||||
| WOS期刊JCR分区 （ 2025-2026年最新版） | 注册或登录后，查看WOS分区等级 | |||||||||||||||||||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版：不在预警名单中 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||||||||||||||||||
  | ||||||||||||||||||||||||||||||||||||||
| 《新锐期刊分区表》 （ 2026年3月发布） | 点击查看期刊分区表趋势图
| |||||||||||||||||||||||||||||||||||||
| 期刊分区表 （ 2025年3月升级版） |
| |||||||||||||||||||||||||||||||||||||
| 期刊分区表 （ 2023年12月旧的升级版） |
| |||||||||||||||||||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) | |||||||||||||||||||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2051-1426%5BISSN%5D | |||||||||||||||||||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 18 Weeks | |||||||||||||||||||||||||||||||||||||
| 平均录用比例 | 网友分享经验： | |||||||||||||||||||||||||||||||||||||
| 版面费/APC文章处理费信息 | 文章处理费：需要（ USD3180; ） 文章处理费豁免：查看说明 其他费用：没有 LetPub提供文章处理费（APC）支持服务，可以用人民币支付版面费啦！ | |||||||||||||||||||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Journal for ImmunoTherapy of Cancer顺利发表。
快看看作者怎么说吧：服务好评 论文致谢（2篇） 。 提交文稿 | |||||||||||||||||||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | LARS2 reprograms mitochondrial metabolism and epigenetically upregulates MHC-I to boost antitumor immunity in nasopharyngeal carcinoma Author: Yang, Mei; Mo, Yongzhen; Ren, Daixi; Liu, Shun; Yan, Qijia; Shi, Lei; Chen, Pan; Xiang, Bo; He, Rongfang; Fan, Songqing; Zhou, Ming; Tan, Ming; Li, Guiyuan; Zu, Xuyu; Zeng, Zhaoyang; Xiong, Wei Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 8, pp. -. DOI: 10.1136/jitc-2026-015098 PubMed DOI |
| 2. | DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy Author: Zhao, Yuanyuan; Wang, Qiming; Xiao, Bijing; Jia, Jun; Liu, Xianling; Ma, Shuxiang; Liu, Hong; Zhou, Ting; Yang, Yunpeng; Fang, Wenfeng; Zhang, Li; Huang, Yan Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 8, pp. -. DOI: 10.1136/jitc-2026-015066 PubMed DOI |
| 3. | AARS1-mediated lactylation reprograms macrophage lipid metabolism to restrict antitumor immunity Author: Xiao, Zhaofeng; Meng, Lijun; Xu, Shengjun; Xu, Nan; Li, Ye; Wang, Jianguo; Tong, Jinyi; Ding, Hongda; Tan, Xiaodong Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 8, pp. -. DOI: 10.1136/jitc-2026-015773 PubMed DOI |
| 4. | PGE2-mediated NK cell reprogramming drives acquired immunotherapy resistance in lung adenocarcinoma Author: Wang, Yajing; Peng, Chen; Feng, Sitong; Wen, Shaodi; Xu, Cong; Du, Xiaoyue; Jiang, Weiwei; Zou, Renrui; Shi, Yue; Ma, Yuejuan; Xu, Zihan; Jiang, Muxi; Shen, Bo Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 8, pp. -. DOI: 10.1136/jitc-2025-014673 PubMed DOI |
| 5. | Targeting GRP75 by natural compound polyphyllin II triggers mitochondrial calcium overload and pyroptosis to potentiate cancer immunotherapy Author: Wang, Yuting; Dong, Jingwen; Long, Yu; Li, Liping; Sun, Cuicui; Li, Ruoqi; Zhang, Jiayu; Liu, Yichen; Yao, Zipeng; Wang, Shuqi; Li, Ke; Yin, Mingxiao; Zhou, Xinbo; Zhang, Na; Deng, Hongbin Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 8, pp. -. DOI: 10.1136/jitc-2026-015043 PubMed DOI |
| 6. | Streptococcus anginosus-associated kynurenic acid drives PD-1 blockade resistance through an ITGA2-mTOR-CTSV axis in gastric cancer Author: Ren, Yingxin; Yu, Xiang; Jiang, Jiaqiang; Luo, Jinlong; Zhao, Cuiyin; Mao, Xinyuan; Xi, Yijie; He, Junting; Yu, Chao; Hu, Yanfeng Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 8, pp. -. DOI: 10.1136/jitc-2026-015172 PubMed DOI |
| 7. | Loss of NCCRP1 overcomes immune evasion in lung adenocarcinoma Author: Liu, Lu; Qi, Shihao; Shao, Liye; Cai, Junyang; Zeng, Qingqing; Jiang, Xu; Ma, Fang; Lin, Weiwei Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 8, pp. -. DOI: 10.1136/jitc-2026-015072 PubMed DOI |
| 8. | TGF-β1 drives neutrophil extracellular traps formation to promote CD8+ T cell exhaustion via the ERK-c-Fos-JunB axis, mediating gastric cancer immunotherapy resistance Author: Qu, Ziting; Wang, Zhikun; Hu, Yongtao; Wei, Xiaoli; Ding, Wenxi; Nomura, Sachiyo; Guo, Xiaoyu; Feng, Hui; Zhang, Yiyin; Gu, Kangsheng Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 8, pp. -. DOI: 10.1136/jitc-2026-015618 PubMed DOI |
| 9. | Yong syndrome-cGAS-STING axis: a TCM syndrome-based hypothesis for overcoming primary anti-PD-1 resistance in gastric cancer Author: Wang, Yinghou; Liu, Guozheng; Li, Yan; Zhou, Lijie; Chen, Yanyan; Zhang, Ye; Xiao, Jingdong; Zhang, Yajie Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 8, pp. -. DOI: 10.1136/jitc-2026-015810 PubMed DOI |
| 10. | β-glucan elicits APOE-dependent peripheral trained immunity to suppress hepatocellular carcinoma Author: Jiang, Nan; Wu, Tong; Yang, Rensheng; He, Guijin; Ding, Bo; Zhu, Can; Liu, Hanqing; Xu, Xinyu; Yang, Beng; Xie, Haiyang; Zheng, Shusen; Tong, Rongliang; Wu, Jian Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2026; Vol. 14, Issue 8, pp. -. DOI: 10.1136/jitc-2026-015401 PubMed DOI |
|
|
  | ||||||||||||||||
|
投稿状态统计： 我要评分： | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范？试试稿件自查工具，一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验：共386条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
投稿信 (Cover Letter) 模板
